MRK — Merck & Co., Inc.

Summary of Merck & Co., Inc. Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Revenue: $16.3 billion, a year-over-year increase of 5% (3% growth excluding foreign exchange impacts).
• Oncology Sales: KEYTRUDA family sales reached $8 billion, up 8%, driven by strong demand in metastatic and earlier-stage cancers.
• GARDASIL Sales: Declined 22% to $1.1 billion due to lower demand in China and Japan.
• Gross Margin: 81.9%, a slight decrease of 0.3 percentage points.
• Operating Expenses: Increased to $15.2 billion, including a $9 billion one-time charge related to the acquisition of Cidara Therapeutics.
• EPS: Reported loss of $1.28 per share, impacted by the Cidara charge.
• Non-GAAP Guidance: Revenue expected between $65.8 billion and $67 billion for 2026, with EPS guidance of $5.04 to $5.16.

2. Strategic Updates and Business Highlights

• Pipeline Progress: FDA approval of IDVYNSO for HIV-1 treatment and priority review for I-DXd for small cell lung cancer.
• New Product Launches: Over 20 new products anticipated, with significant commercial potential.
• Acquisition Strategy: Planned acquisition of Terns Pharmaceuticals, targeting TERN-701 for chronic myeloid leukemia, expected to enhance the oncology pipeline.
• Commercial Structure Evolution: Introduction of a new business unit model to increase agility and accountability.
• AI Initiatives: Partnership with Google Cloud to enhance AI capabilities across the organization.

3. Forward Guidance and Outlook

• 2026 Expectations: Anticipated robust demand for innovative medicines and vaccines, with a focus on maximizing the impact of recent and upcoming product launches.
• Investment Plans: Continued commitment to R&D and business development, with a target of approximately $3 billion in share repurchases for the year.

4. Bad News, Challenges, or Points of Concern

• GARDASIL Sales Decline: Significant drop in sales due to reduced demand in key markets.
• Operating Loss: Reported loss per share primarily due to a one-time charge from an acquisition.
• Competitive Pressures: Concerns regarding the competitive landscape in oncology and the potential impact of recent clinical trial results on ongoing studies.
• Regulatory Risks: Ongoing discussions with the FDA regarding clinical trial designs and approval timelines for new therapies.

5. Notable Q&A Insights

• Pipeline Confidence: Executives expressed optimism about upcoming data readouts and the potential of new therapies, particularly in oncology and cardiometabolic areas.
• Business Development Focus: Continued emphasis on identifying unmet scientific needs and pursuing strategic acquisitions, particularly in oncology and immunology.
• TL1A and Immunology: Discussions on the potential of TL1A to be a significant player in immunology, with plans for future combination therapies.
• Competitive Landscape in HIV: Merck remains committed to its HIV program, emphasizing the unique positioning of its therapies compared to competitors.

Overall, Merck's Q1 2026 results reflect a solid revenue performance driven by oncology, despite challenges in certain vaccine sales and a reported loss due to acquisition-related charges. The company is focused on expanding its pipeline and enhancing its commercial strategy while navigating competitive pressures and regulatory discussions.